High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Kinesin family member 2A (KIF2A) is implicated in various cancers.
• Understanding KIF2A's role in diffuse large B cell lymphoma (DLBCL) is crucial for prognosis and treatment.

Purpose of the Study:

• To investigate KIF2A expression in DLBCL.
• To correlate KIF2A expression with clinical parameters and prognostic indicators.
• To evaluate KIF2A as a prognostic marker in DLBCL.

Main Methods:

• Immunohistochemistry was used to assess KIF2A expression in 134 DLBCL and 57 reactive hyperplasia samples.
• Tissue microarrays were employed for sample analysis.
• Univariate and multivariate analyses were conducted to determine correlations and prognostic value.

Main Results:

• KIF2A expression was significantly higher in DLBCL compared to reactive hyperplasia (P=0.002).
• Elevated KIF2A levels correlated with advanced Ann Arbor stage (P=0.027) and higher international prognostic index (IPI) scores (P=0.01).
• KIF2A expression, serum LDH, and IPI score were independent prognostic markers for DLBCL survival (P=0.016, P=0.049, P<0.001, respectively).

Conclusions:

• Increased KIF2A expression is a significant predictor of poor prognosis in DLBCL patients.
• Downregulating KIF2A reduced DLBCL cell viability and pAKT levels.
• Targeting KIF2A presents a potential therapeutic avenue for DLBCL.